Carbohydrate phosphonate derivatives as modulators of glycosylation

What is this patent about?

’134 is related to the field of carbohydrate chemistry and biotechnology, specifically the modification of protein glycosylation during production in eukaryotic cell cultures. In the manufacture of therapeutic proteins like antibodies, the specific sugar structures attached to the protein—such as fucose and mannose—critically dictate biological activity, including antibody-dependent cellular cytotoxicity (ADCC) and serum clearance rates. Traditional methods for altering these glycan profiles often rely on genetically engineered knockout cell lines, which can suffer from suboptimal growth characteristics and lower product yields.

The underlying idea behind ’134 is the use of synthetic carbohydrate phosphonate derivatives as small-molecule modulators that can be added directly to cell culture media to control glycan incorporation. By designing analogs of fucose, mannose, and N-acetylglucosamine that feature phosphonate-based prodrug moieties, the invention allows for the chemical inhibition or enhancement of specific glycosylation pathways without altering the host cell's genome. This approach provides a tunable means to produce glycoengineered proteins by simply adjusting the concentration or dosing frequency of the small molecule within the bioreactor.

The claims of ’134 focus on a specific class of compounds defined by Formula I, which encompasses three distinct structural variations (IA, IB, and IC) tailored to different sugar pathways. These molecules are characterized by a pyranose core where the traditional anomeric position is replaced by a phosphonate-containing substituent protected by bioreversible groups like pivaloyloxymethyl (POM) or acetoxymethyl. The independent claims cover these chemical structures, which include specific ester-protected hydroxyl groups and various R-group modifications at the C-5 position, such as methyl, trifluoromethyl, or alkynyl groups, to target specific enzymatic machinery.

In practice, these compounds function as metabolic decoys or inhibitors that enter the cell and interact with enzymes like fucosyltransferases or mannosidases. For example, the fucose-based analogs (Formula IA) are utilized to significantly reduce the level of fucose attached to the Fc region of an antibody, thereby enhancing its binding affinity to immune receptors. The implementation involves adding the compound to the culture media in concentrations ranging from 100 nM to 1 mM, with daily dosing demonstrated to be particularly effective at maintaining the desired glycan profile throughout the production cycle.

This invention differentiates itself from prior art by providing a chemical alternative to permanent genetic modifications, offering greater flexibility for biosimilar matching and therapeutic optimization. Unlike general inhibitors like kifunsenine, which can cause unwanted increases in high-mannose structures that lead to rapid drug clearance, the compounds in ’134 are designed for targeted glycan modulation with minimal impact on cell viability or growth. Furthermore, the specific use of phosphonate prodrugs ensures better cellular uptake and stability within the complex environment of a large-scale eukaryotic bioreactor.